Enzo Biochem Return on Tangible Equity 2010-2023 | ENZ

Current and historical return on tangible equity values for Enzo Biochem (ENZ) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Enzo Biochem Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2023-01-31 $-0.04B $0.03B -84.85%
2022-10-31 $-0.03B $0.04B -54.55%
2022-07-31 $-0.02B $0.05B -32.88%
2022-04-30 $-0.01B $0.06B -12.02%
2022-01-31 $0.00B $0.06B 0.00%
2021-10-31 $0.01B $0.06B 8.66%
2021-07-31 $0.01B $0.06B 12.56%
2021-04-30 $0.00B $0.06B 1.89%
2021-01-31 $-0.01B $0.05B -21.05%
2020-10-31 $-0.02B $0.05B -38.53%
2020-07-31 $-0.03B $0.05B -48.95%
2020-04-30 $-0.03B $0.05B -46.79%
2020-01-31 $0.00B $0.06B 1.37%
2019-10-31 $0.00B $0.07B 1.38%
2019-07-31 $0.00B $0.08B 4.20%
2019-04-30 $0.00B $0.08B 2.86%
2019-01-31 $-0.02B $0.06B -33.45%
2018-10-31 $-0.02B $0.07B -21.77%
2018-07-31 $-0.01B $0.07B -14.38%
2018-04-30 $-0.01B $0.08B -6.39%
2018-01-31 $-0.00B $0.08B -2.55%
2017-10-31 $-0.00B $0.08B -2.56%
2017-07-31 $-0.00B $0.08B -2.57%
2017-04-30 $0.03B $0.08B 43.87%
2017-01-31 $0.03B $0.08B 46.89%
2016-10-31 $0.04B $0.08B 67.23%
2016-07-31 $0.05B $0.08B 92.31%
2016-04-30 $0.02B $0.04B 46.58%
2016-01-31 $0.02B $0.04B 51.20%
2015-10-31 $0.01B $0.03B 19.42%
2015-07-31 $-0.00B $0.03B -13.33%
2015-04-30 $-0.01B $0.02B -68.29%
2015-01-31 $-0.01B $0.02B -52.38%
2014-10-31 $-0.01B $0.02B -55.00%
2014-07-31 $-0.01B $0.02B -53.33%
2014-04-30 $-0.01B $0.02B -56.34%
2014-01-31 $-0.02B $0.02B -95.52%
2013-10-31 $-0.02B $0.02B -98.63%
2013-07-31 $-0.02B $0.02B -90.48%
2013-04-30 $-0.04B $0.02B -177.32%
2013-01-31 $-0.04B $0.02B -145.45%
2012-10-31 $-0.04B $0.03B -124.59%
2012-07-31 $-0.04B $0.03B -115.15%
2012-04-30 $-0.02B $0.03B -41.96%
2012-01-31 $-0.01B $0.03B -35.44%
2011-10-31 $-0.02B $0.04B -37.65%
2011-07-31 $-0.01B $0.04B -28.26%
2011-04-30 $-0.02B $0.05B -30.77%
2011-01-31 $-0.02B $0.05B -34.95%
2010-10-31 $-0.02B $0.05B -40.00%
2010-07-31 $-0.02B $0.05B -38.66%
2010-04-30 $-0.02B $0.06B -34.38%
2010-01-31 $-0.02B $0.06B -30.77%
2009-10-31 $-0.02B $0.07B -25.33%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.106B $0.107B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.194B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00